Home › NDC Lookup › Ingredients › Azithromycin › 00093-2027-23
🧴image loading
(from DailyMed)

Azithromycin 100 mg/5mL Powder, For Suspension, 15 mL — NDC 0093-2027-23 (Billing 00093-2027-23)

by Teva Pharmaceuticals USA, Inc. · 15 mL in 1 BOTTLE

This is a package of 15 mL of Azithromycin 100 mg/5mL Powder, For Suspension from Teva Pharmaceuticals USA, Inc., marketed since Dec 2010 and currently FDA-listed; retail pharmacies pay about $0.3702 per mL (NADAC). It is this product's only package size.

NDC 00093-2027-23
🏷️ FDA NDC (as labeled) 0093-2027-23 billing pads the labeler segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0093-2027-23 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0093 labeler · 2027 product · 23 package
Package marketed since
Dec 28, 2010
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
15 mL per package
Barcode (UPC-A, from the NDC)
3 0093202723 7
Medicaid fills, this package
69,219 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0093-2027-23
Product NDC 0093-2027
11-digit billing NDC 00093202723
NCPDP billing unit ML — per mL (volume)
Application # ANDA065246
SPL Set ID 51fdb1a5-1cac-49eb-a6bd-20776c9aa03b
Established class (EPC) Macrolide Antimicrobial
Chemical class Macrolides
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2010-12-28
Route ORAL
Dosage form POWDER, FOR SUSPENSION
Substance AZITHROMYCIN MONOHYDRATE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 024194
GCN 48792
HICL code 006334
Ingredient (HICL) Azithromycin
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W1
Therapeutic class — intermediate (HIC2) Antibiotics
HIC3 code W1D
Therapeutic class — specific (HIC3) Macrolide Antibiotics
AHFS code 08:12.12.08
AHFS class Other Macrolide Antibiotics
FDB label name AZITHROMYCIN 100 MG/5 ML SUSP
FDB brand name Azithromycin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 024194
  • GCN: 48792
  • HICL (First Databank): 006334
  • AHFS class code: 08:12.12.08
Why two NDCs? The FDA registers this code as 0093-2027-23 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00093-2027-23. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name AZITHROMYCIN 100 MG/5 ML SUSP Ingredient Azithromycin
📖 What it is MedlinePlus · NLM

Azithromycin is used to treat infections caused by bacteria. It is also used to treat and prevent disseminated Mycobacterium avium complex (MAC) infection [a type of lung infection that affects people with a suppressed immune system). Azithromycin is in a class of medications called macrolide antibiotics. It works by stopping the growth of bacteria. Antibiotics such as azithromycin will not work for colds, flu, or other viral infections. Using antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats certain bacterial infections, such as sinus infections, pneumonia, bronchitis flare-ups, strep-type throat infections, ear infections in children, skin infections and som...
  • The tablets can be taken with or without food. If it upsets your stomach, taking it with a meal may help. Follow the directions on your label.
  • The most common are diarrhea, nausea, stomach pain and vomiting, and they are usually mild. Call your doctor if you have a rash, swelling, yellow skin or eyes, a racing or irregula...
  • Tell me about everything you take. Azithromycin may increase the effect of warfarin, so your clotting tests should be monitored. Medicines that affect heart rhythm, such as amiodar...
📖 Read our full Azithromycin guide →
7
Nutrient depletion considerations

Azithromycin may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Azithromycin nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.370 $5.55 / 15 ml
Medicaid paysCMS SDUD · 12 mo $0.6798 $10.20 / 15 ml
Medicare drug plans payPart D · Q2 2026 $0.3238 $4.86 / 15 ml
NADAC price history (per mL) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.582 $0.353
▼ Down 36% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00093-2027-23 You're viewing this Main listing 15 mL in 1 BOTTLE 2010-12-28 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Azithromycin 100 mg/5mLthis 00093-2027-23 Teva 15 ml $0.370 AB Availability likely —
Azithromycin 100 mg/5mL 11788-0128-13 AiPing 1 bottle $0.370 AB Availability likely —
Azithromycin 100 mg/5mL 42806-0147-31 Epic 15 ml $0.370 AB Availability likely —
Azithromycin 100 mg/5mL 59651-0007-15 Aurobindo 1 bottle $0.370 AB Availability likely —
Azithromycin 100 mg/5mL 70710-1457-01 Zydus 1 bottle $0.370 AB Availability likely —
azithromycin dihydrate 100 mg/5mL 70436-0220-34 Slate 1 bottle $0.389 AB Availability likely +5%
Azithromycin 100 mg/5mL 50090-1868-00 A-S 15 ml — AB FDA listed —
Azithromycin 100 mg/5mL 55695-0002-00 STATE 15 ml — AB FDA listed —
Azithromycin 100 mg/5mL 62135-0704-51 Chartwell 15 ml — AB FDA listed —
Azithromycin 100 mg/5mL 68071-1527-05 NuCare 15 ml — AB FDA listed —
Azithromycin 100 mg/5mL 68071-5035-05 NuCare 15 ml — AB FDA listed —
Azithromycin 100 mg/5mL 68788-8675-01 Preferred 15 ml — AB FDA listed —
Azithromycin 100 mg/5mL 70771-1422-01 Zydus 1 bottle — AB FDA listed —
Azithromycin 100 mg/5mL 72673-0084-30 Zhejiang 1 bottle — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2010
On the market since
Dec 2010
📍
2026
Currently FDA-listed
16 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Azithromycin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerTeva Pharmaceuticals USA, Inc.
Application holderPLIVA INC
FDA applicationANDA065246 (ANDA)
Labeler code00093
First marketedDec 2010
Product typeHuman Prescription Drug
Portfolio504 products on file

More NDCs from Teva Pharmaceuticals USA, Inc. labeler code 00093

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
69.2K
Units reimbursed last 4 qtrs
1.8M
Gross reimbursed last 4 qtrs
$1.24M
Avg / prescription
$17.96
Avg / unit
$0.6798
Latest quarter Q1 2026
19.2KRx
Medicaid pays / mL
$0.6798
gross reimbursed
vs
NADAC / mL
$0.3702
acquisition cost
=
Spread
+$0.3096
+84% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
41% FFS 59% MCO
Fee-for-service · 28,504 Rx Managed care · 40,715 Rx
State Medicaid map
Alaska: no data reported AK Maine: 3,105 units · 223 per 100k residents ME Washington: 8,535 units · 109 per 100k residents WA Idaho: 3,240 units · 165 per 100k residents ID Montana: 826 units · 73.0 per 100k residents MT North Dakota: no data reported ND Minnesota: 17,746 units · 309 per 100k residents MN Wisconsin: 14,235 units · 241 per 100k residents WI Michigan: 65,119 units · 649 per 100k residents MI New York: 58,407 units · 298 per 100k residents NY Vermont: 260 units · 40.2 per 100k residents VT New Hampshire: 1,080 units · 77.0 per 100k residents NH Oregon: 4,530 units · 107 per 100k residents OR Nevada: 17,250 units · 540 per 100k residents NV Wyoming: 1,080 units · 185 per 100k residents WY South Dakota: 365 units · 39.7 per 100k residents SD Iowa: 8,360 units · 261 per 100k residents IA Illinois: 50,193 units · 400 per 100k residents IL Indiana: 11,421 units · 166 per 100k residents IN Ohio: 19,963 units · 169 per 100k residents OH Pennsylvania: 8,760 units · 67.6 per 100k residents PA New Jersey: 25,161 units · 271 per 100k residents NJ Massachusetts: 5,191 units · 74.1 per 100k residents MA California: 521,381 units · 1,338 per 100k residents CA Utah: 2,160 units · 63.2 per 100k residents UT Colorado: 7,710 units · 131 per 100k residents CO Nebraska: 7,645 units · 387 per 100k residents NE Missouri: 17,655 units · 285 per 100k residents MO Kentucky: 29,472 units · 651 per 100k residents KY West Virginia: 8,850 units · 500 per 100k residents WV Virginia: 5,355 units · 61.4 per 100k residents VA Maryland: 9,295 units · 150 per 100k residents MD Connecticut: 7,770 units · 215 per 100k residents CT Rhode Island: 1,575 units · 144 per 100k residents RI Arizona: 35,775 units · 481 per 100k residents AZ New Mexico: 25,227 units · 1,193 per 100k residents NM Kansas: 4,678 units · 159 per 100k residents KS Arkansas: 18,810 units · 613 per 100k residents AR Tennessee: 48,043 units · 674 per 100k residents TN North Carolina: 46,440 units · 429 per 100k residents NC South Carolina: 7,285 units · 136 per 100k residents SC Delaware: 2,940 units · 285 per 100k residents DE Oklahoma: 15,233 units · 376 per 100k residents OK Louisiana: 63,418 units · 1,386 per 100k residents LA Mississippi: 44,386 units · 1,510 per 100k residents MS Alabama: 40,020 units · 783 per 100k residents AL Georgia: 14,865 units · 135 per 100k residents GA D.C.: no data reported DC Hawaii: 7,845 units · 547 per 100k residents HI Texas: 244,214 units · 801 per 100k residents TX Florida: 250,625 units · 1,108 per 100k residents FL
Units reimbursed · per 100k residents
39.71,510
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Mississippi 1,510 /100k
2 Louisiana 1,386 /100k
3 California 1,338 /100k
4 New Mexico 1,193 /100k
5 Florida 1,108 /100k
6 Texas 801 /100k
7 Alabama 783 /100k
8 Tennessee 674 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Azithromycin — the program that covers self-administered drugs. 19 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Azithromycin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$13.72M
Claims incl. refills
2.4M
Beneficiaries
2.2M
Spend / beneficiary
$6.32
Spend / claim
$5.61
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 00093-2026-23 · Teva 00093-2063-01 · Teva →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.